Genentech's Rituxan, Others, Under Fire From Sanofi

Law360, New York (October 27, 2008, 12:00 AM EDT) -- Germany-based pharmaceutical company Sanofi-Aventis Deutschland GmbH has sued Genentech Inc. and Biogen Idec Inc. over two patents allegedly infringed by the companies' manufacture and sale of drugs used to treat diseases including cancer, pulmonary embolism and cystic fibrosis.

Genentech's nonexclusive license to make use of the two patents-at-issue is set to terminate on Monday, according to the complaint filed the same day in the U.S. District Court for the Eastern District of Texas.

Genentech has produced several drugs using mammalian cell suspension cultures that utilize the...
To view the full article, register now.